Prospects for nucleic acid-based therapeutics against hepatitis C virus

World Journal of Gastroenterology

Volumn 19, Issue 47, 2013, Pages 8949-8962

  Lee, Chang Ho ^a   Kim, Ji Hyun ^a   Lee, Seong Wook ^a  

^a Dankook University   (South Korea)

Author keywords

Antisense oligo nucleotide; Aptamer; Hepatitis C virus; Nucleic acid based therapeutics; Ribozyme; SiRNA

Indexed keywords

AGENTS AFFECTING NUCLEIC ACID METABOLISM; ALLOSTERIC RIBOZYME; ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; APTAMER; BOCEPREVIR; DEOXYRIBOZYME; FOMIVIRSEN; GENOMIC RNA; HAIRPIN RIBOZYME; HAMMERHEAD RIBOZYME; HEPATITIS DELTA VIRUS RIBOZYME; HEPATOZYME; ISIS 14803; LOCKED NUCLEIC ACID; MICRORNA 122; MIPOMERSEN; MIRAVIRSEN; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5B; PARVOVIRUS VECTOR; PEPTIDE NUCLEIC ACID; RIBAVIRIN; RIBONUCLEASE P; RIBOZYME; RNA INDUCED SILENCING COMPLEX; SELF SPLICING RIBOSOMAL RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANTISENSE THERAPY; ARTICLE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOGENICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RNA INTERFERENCE; TETRAHYMENA THERMOPHILA; VIRUS GENOME; VIRUS REPLICATION;

ANTISENSE OLIGONUCLEOTIDE; APTAMER; HEPATITIS C VIRUS; NUCLEIC ACID-BASED THERAPEUTICS; RIBOZYME; SIRNA;

ANIMALS; ANTIVIRAL AGENTS; APTAMERS, NUCLEOTIDE; DRUG DESIGN; GENETIC THERAPY; HEPACIVIRUS; HEPATITIS C; HUMANS; NUCLEIC ACIDS; OLIGONUCLEOTIDES, ANTISENSE; RNA INTERFERENCE; RNA, CATALYTIC; RNA, SMALL INTERFERING; TREATMENT OUTCOME;

EID: 84890928825     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i47.8949     Document Type: Article

References (144)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52 [PMID: 11439948 DOI: 10.1056/ NEJM200107053450107]
2. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-2441 [PMID: 17552026]
3. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538 [PMID: 16879891 DOI: 10.1016/ j.jhep.2006.05.013]
4. Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Pren-toe JC, Knudsen ML, Hoegh AM, Bukh J. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009; 49: 364-377 [PMID: 19148942 DOI: 10.1002/hep.22673]
5. Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 2011; 239: 99-108 [PMID: 21198667 DOI: 10.1111/j.1600-065X.2010.00977.x]
6. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 2013; 11: 482-496 [PMID: 23748342 DOI: 10.1038/nrmicro3046]
7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982 [PMID: 12324553 DOI: 10.1056/ NEJMoa020047]
8. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: effcacy, side effects, and complications. Gut 2006; 55: 1350-1359 [PMID: 16905701 DOI: 10.1136/gut.2005.076646]
9. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46: 631-639 [PMID: 17680654 DOI: 10.1002/ hep.21781]
10. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010; 65: 202-212 [PMID: 19903720 DOI: 10.1093/jac/dkp388]
11. Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol 2012; 19: 60-71 [PMID: 22284355 DOI: 10.1016/j.chembiol.2011.12.008]
12. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012; 11: 125-140 [PMID: 22262036 DOI: 10.1038/nrd3625]
13. Wilson RC, Doudna JA. Molecular mechanisms of RNA interference. Annu Rev Biophys 2013; 42: 217-239 [PMID: 23654304 DOI: 10.1146/annurev-biophys-083012-130404]
14. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012; 3: 1 [PMID: 22230293 DOI: 10.1186/1758-907X-3-1]
15. Mulhbacher J, St-Pierre P, Lafontaine DA. Therapeutic applications of ribozymes and riboswitches. Curr Opin Pharmacol 2010; 10: 551-556 [PMID: 20685165 DOI: 10.1016/ j.coph.2010.07.002]
16. Andrei G, De Clercq E, Snoeck R. Drug targets in cytomega-lovirus infection. Infect Disord Drug Targets 2009; 9: 201-222 [PMID: 19275707 DOI: 10.2174/187152609787847758]
17. Toth PP. Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholes-terolemia. J Clin Lipidol 2013; 7: S6-10 [PMID: 23642326 DOI: 10.1016/j.jacl.2013.02.004]
18. Rinaldi M, Chiosi F, Dell'Omo R, Romano MR, Parmeggiani F, Semeraro F, Mastropasqua R, Costagliola C. Intravitreal pegaptanib sodium (Macugen®) for treatment of diabetic macular oedema: a morphologic and functional study. Br J Clin Pharmacol 2012; 74: 940-946 [PMID: 22486651 DOI: 10.1111/j.1365-2125.2012.04291.x]
19. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. Treatment of HCV infection by targeting mi-croRNA. N Engl J Med 2013; 368: 1685-1694 [PMID: 23534542 DOI: 10.1056/NEJMoa1209026]
20. Serganov A, Patel DJ. Ribozymes, riboswitches and beyond: regulation of gene expression without proteins. Nat Rev Genet 2007; 8: 776-790 [PMID: 17846637]
21. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000; 81: 1631-1648 [PMID: 10859368]
22. Ohkawa K, Yuki N, Kanazawa Y, Ueda K, Mita E, Sasaki Y, Kasahara A, Hayashi N. Cleavage of viral RNA and inhibition of viral translation by hepatitis C virus RNA-specifc hammerhead ribozyme in vitro. J Hepatol 1997; 27: 78-84 [PMID: 9252077 DOI: 10.1016/S0168-8278(97)80283-8]
23. Sakamoto N, Wu CH, Wu GY. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J Clin Invest 1996; 98: 2720-2728 [PMID: 8981917 DOI: 10.1172/JCI119097]
24. Welch PJ, Tritz R, Yei S, Leavitt M, Yu M, Barber J. A potential therapeutic application of hairpin ribozymes: in vitro and in vivo studies of gene therapy for hepatitis C virus infection. Gene Ther 1996; 3: 994-1001 [PMID: 9044745]
25. Welch PJ, Yei S, Barber JR. Ribozyme gene therapy for hepatitis C virus infection. Clin Diagn Virol 1998; 10: 163-171 [PMID: 9741642 DOI: 10.1016/S0928-0197(98)00029-4]
26. Puerta-Fernández E, Romero-López C, Barroso-delJesus A, Berzal-Herranz A. Ribozymes: recent advances in the development of RNA tools. FEMS Microbiol Rev 2003; 27: 75-97[PMID: 12697343 DOI: 10.1016/S0168-6445(03)00020-2]
27. Müller S, Appel B, Krellenberg T, Petkovic S. The many faces of the hairpin ribozyme: structural and functional variants of a small catalytic RNA. IUBMB Life 2012; 64: 36-47[PMID: 22131309 DOI: 10.1002/iub.575]
28. Jarczak D, Korf M, Beger C, Manns MP, Krüger M. Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons. FEBS J 2005; 272: 5910-5922[PMID: 16279954 DOI: 10.1111/j.1742-4658.2005.04986.x]
29. Asif-Ullah M, Lévesque M, Robichaud G, Perreault JP. Development of ribozyme-based gene-inactivations; the example of the hepatitis delta virus ribozyme. Curr Gene Ther 2007; 7: 205-216[PMID: 17584038 DOI: 10.2174/15665230778 0859008]
30. Yu YC, Mao Q, Gu CH, Li QF, Wang YM. Activity of HDV ribozymes to trans-cleave HCV RNA. World J Gastroenterol 2002; 8: 694-698[PMID: 12174380]
31. Lévesque MV, Lévesque D, Brière FP, Perreault JP. Investigating a new generation of ribozymes in order to target HCV. PLoS One 2010; 5: e9627[PMID: 20224783 DOI: 10.1371/journal.pone.0009627]
32. Gonzalez-Carmona MA, Schüssler S, Serwe M, Alt M, Lud-wig J, Sproat BS, Steigerwald R, Hoffmann P, Quasdorff M, Schildgen O, Caselmann WH. Hammerhead ribozymes with cleavage site specifcity for NUH and NCH display signif-cant anti-hepatitis C viral effect in vitro and in recombinant HepG2 and CCL13 cells. J Hepatol 2006; 44: 1017-1025[PMID: 16469406 DOI: 10.1016/j.jhep.2005.10.022]
33. Macejak DG, Jensen KL, Jamison SF, Domenico K, Roberts EC, Chaudhary N, von Carlowitz I, Bellon L, Tong MJ, Conrad A, Pavco PA, Blatt LM. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chi-meric HCV poliovirus using synthetic stabilized ribozymes. Hepatology 2000; 31: 769-776[PMID: 10706571 DOI: 10.1002/ hep.510310331]
34. Macejak DG, Jensen KL, Pavco PA, Phipps KM, Heinz BA, Colacino JM, Blatt LM. Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA. J Viral Hepat 2001; 8: 400-405[PMID: 11703570 DOI: 10.1046/j.1365-2893.2001.00321.x]
35. Lee PA, Blatt LM, Blanchard KS, Bouhana KS, Pavco PA, Bellon L, Sandberg JA. Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice. Hepatology 2000; 32: 640-646[PMID: 10960462 DOI: 10.1053/jhep.2000.16599]
36. Swan T, Raymond D. Hepatitis C virus (HCV) and HIV/ HCV coinfection: A critical review of research and treatment. New York: Treatment Action Group, 2004
37. Kashani-Sabet M. Ribozyme therapeutics. J Investig Derma-tol Symp Proc 2002; 7: 76-78[PMID: 12518796 DOI: 10.1046/j.1523-1747.2002.19642.x]
38. Steele D, Kertsburg A, Soukup GA. Engineered catalytic RNA and DNA: new biochemical tools for drug discovery and design. Am J Pharmacogenomics 2003; 3: 131-144[PMID: 12749730 DOI: 10.2165/00129785-200303020-00006]
39. Trepanier J, Tanner JE, Momparler RL, Le ON, Alvarez F, Alferi C. Cleavage of intracellular hepatitis C RNA in the virus core protein coding region by deoxyribozymes. J Viral Hepat 2006; 13: 131-138[PMID: 16436131 DOI: 10.1111/ j.1365-2893.2005.00684.x]
40. Kumar D, Chaudhury I, Kar P, Das RH. Site-specifc cleavage of HCV genomic RNA and its cloned core and NS5B genes by DNAzyme. J Gastroenterol Hepatol 2009; 24: 872-878[PMID: 19220662 DOI: 10.1111/j.1440-1746.2008.05717.x]
41. Roy S, Gupta N, Subramanian N, Mondal T, Banerjea AC, Das S. Sequence-specifc cleavage of hepatitis C virus RNA by DNAzymes: inhibition of viral RNA translation and replication. J Gen Virol 2008; 89: 1579-1586[PMID: 18559927 DOI: 10.1099/vir.0.83650-0]
42. Lee B, Kim KB, Oh S, Choi JS, Park JS, Min DH, Kim DE. Suppression of hepatitis C virus genome replication in cells with RNA-cleaving DNA enzymes and short-hairpin RNA. Oligonucleotides 2010; 20: 285-296[PMID: 20863235 DOI: 10.1089/oli.2010.0256]
43. James HA, Gibson I. The therapeutic potential of ribozymes. Blood 1998; 91: 371-382[PMID: 9427689]
44. Yuan Y, Altman S. Selection of guide sequences that direct effcient cleavage of mRNA by human ribonuclease P. Science 1994; 263: 1269-1273[PMID: 8122108 DOI: 10.1126/sci-ence.8122108]
45. Nadal A, Martell M, Lytle JR, Lyons AJ, Robertson HD, Cabot B, Esteban JI, Esteban R, Guardia J, Gómez J. Specifc cleavage of hepatitis C virus RNA genome by human RNase P. J Biol Chem 2002; 277: 30606-30613[PMID: 12060655 DOI: 10.1074/jbc.M203595200]
46. Nadal A, Robertson HD, Guardia J, Gómez J. Characterization of the structure and variability of an internal region of hepatitis C virus RNA for M1 RNA guide sequence ribozyme targeting. J Gen Virol 2003; 84: 1545-1548[PMID: 12771424 DOI: 10.1099/vir.0.18898-0]
47. Sabariegos R, Nadal A, Beguiristain N, Piron M, Gómez J. Catalytic RNase P RNA from Synechocystis sp. cleaves the hepatitis C virus RNA near the AUG start codon. FEBS Lett 2004; 577: 517-522[PMID: 15556639 DOI: 10.1016/ j.febslet.2004.10.059]
48. Been MD, Cech TR. One binding site determines sequence specificity of Tetrahymena pre-rRNA self-splicing, trans-splicing, and RNA enzyme activity. Cell 1986; 47: 207-216[PMID: 3021333 DOI: 10.1016/0092-8674(86)90443-5]
49. Sullenger BA, Cech TR. Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing. Nature 1994; 371: 619-622[PMID: 7935797 DOI: 10.1038/371619a0]
50. Jones JT, Lee SW, Sullenger BA. Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells. Nat Med 1996; 2: 643-648[PMID: 8640554 DOI: 10.1038/nm0696-643]
51. Ryu KJ, Kim JH, Lee SW. Ribozyme-mediated selective induction of new gene activity in hepatitis C virus internal ribosome entry site-expressing cells by targeted trans-splicing. Mol Ther 2003; 7: 386-395[PMID: 12668134 DOI: 10.1016/S1525-0016(02)00063-1]
52. Bergeron LJ, Reymond C, Perreault JP. Functional characterization of the SOFA delta ribozyme. RNA 2005; 11: 1858-1868[PMID: 16251383 DOI: 10.1261/rna.2112705]
53. Bergeron LJ, Perreault JP. Target-dependent on/off switch increases ribozyme fidelity. Nucleic Acids Res 2005; 33: 1240-1248[PMID: 15731344 DOI: 10.1093/nar/gki278]
54. Lee CH, Kim JH, Kim HW, Myung H, Lee SW. Hepatitis C virus replication-specific inhibition of microRNA activity with self-cleavable allosteric ribozyme. Nucleic Acid Ther 2012; 22: 17-29[PMID: 22217271 DOI: 10.1089/nat.2011.0326]
55. Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685-689[PMID: 16258535 DOI: 10.1038/nature04303]
56. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87-98[PMID: 16459310 DOI: 10.1016/j.cmet.2006.01.005]
57. Elmén J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, Hedtjärn M, Hansen JB, Hansen HF, Straarup EM, McCullagh K, Kearney P, Kauppinen S. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008; 36: 1153-1162[PMID: 18158304 DOI: 10.1093/nar/gkm1113]
58. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sab-bioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E, Grazi GL, Croce CM, Bolondi L, Negrini M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67: 6092-6099[PMID: 17616664 DOI: 10.1158/0008-5472. CAN-06-4607]
59. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, Hsu MT, Hsiao M, Huang HD, Tsou AP. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepa-tocellular carcinoma. Hepatology 2009; 49: 1571-1582[PMID: 19296470 DOI: 10.1002/hep.22806]
60. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, Hsu MT, Wu JC, Huang HD, Shiao MS, Hsiao M, Tsou AP. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012; 122: 2884-2897[PMID: 22820290 DOI: 10.1172/ JCI63455]
61. Kaur G, Roy I. Therapeutic applications of aptamers. Expert Opin Investig Drugs 2008; 17: 43-60[PMID: 18095918 DOI: 10.1517/13543784.17.1.43]
62. Que-Gewirth NS, Sullenger BA. Gene therapy progress and prospects: RNA aptamers. Gene Ther 2007; 14: 283-291[PMID: 17279100 DOI: 10.1038/sj.gt.3302900]
63. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249: 505-510[PMID: 2200121]
64. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specifc ligands. Nature 1990; 346: 818-822[PMID: 1697402 DOI: 10.1038/346818a0]
65. Nakamura Y, Ishiguro A, Miyakawa S. RNA plasticity and selectivity applicable to therapeutics and novel biosensor development. Genes Cells 2012; 17: 344-364[PMID: 22487172 DOI: 10.1111/j.1365-2443.2012.01596.x]
66. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113[PMID: 10390360 DOI: 10.1126/science.285.5424.110]
67. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizo-kami M, Bartenschlager R, Liang TJ. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796[PMID: 15951748 DOI: 10.1038/nm1268]
68. Nishikawa F, Kakiuchi N, Funaji K, Fukuda K, Sekiya S, Nishikawa S. Inhibition of HCV NS3 protease by RNA ap-tamers in cells. Nucleic Acids Res 2003; 31: 1935-1943[PMID: 12655010 DOI: 10.1093/nar/gkg291]
69. Nishikawa F, Funaji K, Fukuda K, Nishikawa S. In vitro selection of RNA aptamers against the HCV NS3 helicase domain. Oligonucleotides 2004; 14: 114-129[PMID: 15294075 DOI: 10.1089/1545457041526335]
70. Hwang B, Cho JS, Yeo HJ, Kim JH, Chung KM, Han K, Jang SK, Lee SW. Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus. RNA 2004; 10: 1277-1290[PMID: 15247433 DOI: 10.1261/ rna.7100904]
71. Umehara T, Fukuda K, Nishikawa F, Sekiya S, Kohara M, Hasegawa T, Nishikawa S. Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3. Nucleic Acids Symp Ser (Oxf) 2004;: 195-196[PMID: 17150545 DOI: 10.1093/nass/48.1.195]
72. Blight KJ, Kolykhalov AA, Rice CM. Effcient initiation of HCV RNA replication in cell culture. Science 2000; 290: 1972-1974[PMID: 11110665 DOI: 10.1126/science.290.5498.1972]
73. Grobler JA, Markel EJ, Fay JF, Graham DJ, Simcoe AL, Lud-merer SW, Murray EM, Migliaccio G, Flores OA. Identifca-tion of a key determinant of hepatitis C virus cell culture adaptation in domain II of NS3 helicase. J Biol Chem 2003; 278: 16741-16746[PMID: 12615931 DOI: 10.2174/1389557057 74933310]
74. Wu JZ, Yao N, Walker M, Hong Z. Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase. Mini Rev Med Chem 2005; 5: 1103-1112[PMID: 16375756 DOI: 10.1128/AAC.01603-05]
75. Jones LA, Clancy LE, Rawlinson WD, White PA. High-affnity aptamers to subtype 3a hepatitis C virus polymerase display genotypic specifcity. Antimicrob Agents Chemother 2006; 50: 3019-3027[PMID: 16940097]
76. Saeed M, Gondeau C, Hmwe S, Yokokawa H, Date T, Suzuki T, Kato T, Maurel P, Wakita T. Replication of hepatitis C virus genotype 3a in cultured cells. Gastroenterology 2013; 144: 56-58.e7[PMID: 22999961 DOI: 10.1053/j.gastro.2012.09.017]
77. Bellecave P, Cazenave C, Rumi J, Staedel C, Cosnefroy O, Andreola ML, Ventura M, Tarrago-Litvak L, Astier-Gin T. Inhibition of hepatitis C virus (HCV) RNA polymerase by DNA aptamers: mechanism of inhibition of in vitro RNA synthesis and effect on HCV-infected cells. Antimicrob Agents Chemother 2008; 52: 2097-2110[PMID: 18347106 DOI: 10.1128/AAC.01227-07]
78. Lee CH, Lee YJ, Kim JH, Lim JH, Kim JH, Han W, Lee SH, Noh GJ, Lee SW. Inhibition of hepatitis C virus (HCV) replication by specifc RNA aptamers against HCV NS5B RNA replicase. J Virol 2013; 87: 7064-7074[PMID: 23596299 DOI: 10.1128/JVI.00405-13]
79. Yang D, Meng X, Yu Q, Xu L, Long Y, Liu B, Fang X, Zhu H. Inhibition of hepatitis C virus infection by DNA aptamer against envelope protein. Antimicrob Agents Chemother 2013; 57: 4937-4944[PMID: 23877701 DOI: 10.1128/AAC.00897-13]
80. Kikuchi K, Umehara T, Fukuda K, Kuno A, Hasegawa T, Nishikawa S. A hepatitis C virus (HCV) internal ribosome entry site (IRES) domain III-IV-targeted aptamer inhibits translation by binding to an apical loop of domain IIId. Nucleic Acids Res 2005; 33: 683-692[PMID: 15681618 DOI: 10.1093/nar/gki215]
81. Marton S, Romero-López C, Berzal-Herranz A. RNA ap-tamer-mediated interference of HCV replication by targeting the CRE-5BSL3.2 domain. J Viral Hepat 2013; 20: 103-112[PMID: 23301545 DOI: 10.1111/j.1365-2893.2012.01629.x]
82. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811[PMID: 9486653 DOI: 10.1038/35888]
83. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007; 8: 173-184[PMID: 17304245 DOI: 10.1038/nrg2006]
84. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409: 363-366[PMID: 11201747 DOI: 10.1038/35053110]
85. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000; 101: 25-33[PMID: 10778853 DOI: 10.1016/S0092-8674(00)80620-0]
86. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 2005; 123: 607-620[PMID: 16271386 DOI: 10.1016/j.cell.2005.08.044]
87. Rand TA, Petersen S, Du F, Wang X. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell 2005; 123: 621-629[PMID: 16271385 DOI: 10.1016/ j.cell.2005.10.020]
88. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001; 15: 188-200[PMID: 11157775 DOI: 10.1101/gad.862301]
89. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297[PMID: 14744438 DOI: 10.1016/S0092-8674(04)00045-5]
90. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498[PMID: 11373684 DOI: 10.1038/35078107]
91. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004; 431: 371-378[PMID: 15372045 DOI: 10.1038/nature02870]
92. Mittal V. Improving the effciency of RNA interference in mammals. Nat Rev Genet 2004; 5: 355-365[PMID: 15143318 DOI: 10.1038/nrg1323]
93. Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, Maekawa S, Yi L, Kurosaki M, Taira K, Watanabe M, Mizusawa H. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep 2003; 4: 602-608[PMID: 12740604 DOI: 10.1038/sj.embor.embor840]
94. Motavaf M, Safari S, Alavian SM. Therapeutic potential of RNA interference: a new molecular approach to antiviral treatment for hepatitis C. J Viral Hepat 2012; 19: 757-765[PMID: 23043382 DOI: 10.1111/jvh.12006]
95. Seo MY, Abrignani S, Houghton M, Han JH. Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. J Virol 2003; 77: 810-812[PMID: 12477890 DOI: 10.1128/ JVI.77.1.810-812.2003]
96. Prabhu R, Garry RF, Dash S. Small interfering RNA targeted to stem-loop II of the 5' untranslated region effectively inhibits expression of six HCV genotypes. Virol J 2006; 3: 100[PMID: 17129382 DOI: 10.1186/1743-422X-3-100]
97. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553[PMID: 11910072 DOI: 10.1126/science.1068999]
98. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specifc silencing in mammalian cells. Genes Dev 2002; 16: 948-958[PMID: 11959843 DOI: 10.1101/gad.981002]
99. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ. Synthetic dsRNA Dicer substrates enhance RNAi potency and effcacy. Nat Biotechnol 2005; 23: 222-226[PMID: 15619617 DOI: 10.1038/nbt1051]
100. Watanabe T, Sudoh M, Miyagishi M, Akashi H, Arai M, Inoue K, Taira K, Yoshiba M, Kohara M. Intracellular-diced dsRNA has enhanced effcacy for silencing HCV RNA and overcomes variation in the viral genotype. Gene Ther 2006; 13: 883-892[PMID: 16496015]
101. Kanda T, Steele R, Ray R, Ray RB. Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect. J Virol 2007; 81: 669-676[PMID: 17079316 DOI: 10.1128/JVI.01496-06]
102. Ray RB, Kanda T. Inhibition of HCV replication by small interfering RNA. Methods Mol Biol 2009; 510: 251-262[PMID: 19009267 DOI: 10.1007/978-1-59745-394-3_19]
103. Randall G, Grakoui A, Rice CM. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci USA 2003; 100: 235-240[PMID: 12518066 DOI: 10.1073/pnas.0235524100]
104. Liu M, Ding H, Zhao P, Qin ZL, Gao J, Cao MM, Luan J, Wu WB, Qi ZT. RNA interference effectively inhibits mRNA accumulation and protein expression of hepatitis C virus core and E2 genes in human cells. Biosci Biotechnol Biochem 2006; 70: 2049-2055[PMID: 16960393 DOI: 10.1271/bbb.60001]
105. Kim M, Shin D, Kim SI, Park M. Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model. Virus Res 2006; 122: 1-10[PMID: 16979254 DOI: 10.1016/j.virusres.2006.05.003]
106. Ansar M, Ashfaq UA, Shahid I, Sarwar MT, Javed T, Rehman S, Hassan S, Riazuddin S. Inhibition of full length hepatitis C virus particles of 1a genotype through small interference RNA. Virol J 2011; 8: 203[PMID: 21535893 DOI: 10.1186/1743-422X-8-203]
107. Ali Ashfaq U, Ansar M, Sarwar MT, Javed T, Rehman S, Ri-azuddin S. Post-transcriptional inhibition of hepatitis C virus replication through small interference RNA. Virol J 2011; 8: 112[PMID: 21388559 DOI: 10.1186/1743-422X-8-112]
108. Kapadia SB, Brideau-Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA 2003; 100: 2014-2018[PMID: 12566571 DOI: 10.1073/pnas.252783999]
109. Wilson JA, Jayasena S, Khvorova A, Sabatinos S, Rodrigue-Gervais IG, Arya S, Sarangi F, Harris-Brandts M, Beaulieu S, Richardson CD. RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc Natl Acad Sci USA 2003; 100: 2783-2788[PMID: 12594341 DOI: 10.1073/pnas.252758799]
110. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodo-lets KE, Pfeffer S, Landthaler M, Landgraf P, Kan S, Lin-denbach BD, Chien M, Weir DB, Russo JJ, Ju J, Brownstein MJ, Sheridan R, Sander C, Zavolan M, Tuschl T, Rice CM. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci USA 2007; 104: 12884-12889[PMID: 17616579]
111. Ng TI, Mo H, Pilot-Matias T, He Y, Koev G, Krishnan P, Mondal R, Pithawalla R, He W, Dekhtyar T, Packer J, Sch-urdak M, Molla A. Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology. Hepatology 2007; 45: 1413-1421[PMID: 17518369 DOI: 10.1002/hep.21608]
112. Supekova L, Supek F, Lee J, Chen S, Gray N, Pezacki JP, Schlapbach A, Schultz PG. Identifcation of human kinases involved in hepatitis C virus replication by small interference RNA library screening. J Biol Chem 2008; 283: 29-36[PMID: 17951261 DOI: 10.1074/jbc.M703988200]
113. Tai AW, Benita Y, Peng LF, Kim SS, Sakamoto N, Xavier RJ, Chung RT. A functional genomic screen identifes cellular cofactors of hepatitis C virus replication. Cell Host Microbe 2009; 5: 298-307[PMID: 19286138 DOI: 10.1016/ j.chom.2009.02.001]
114. Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, Wakita T, Jaeck D, Doffoel M, Royer C, Soulier E, Schvoerer E, Schuster C, Stoll-Keller F, Bartenschlager R, Pietschmann T, Barth H, Baumert TF. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 2007; 46: 1722-1731[PMID: 18000990 DOI: 10.1002/hep.21994]
115. Jahan S, Samreen B, Khaliq S, Ijaz B, Khan M, Siddique MH, Ahmad W, Hassan S. HCV entry receptors as potential targets for siRNA-based inhibition of HCV. Genet Vaccines Ther 2011; 9: 15[PMID: 21896165 DOI: 10.1186/1479-0556-9-15]
116. Jahan S, Khaliq S, Samreen B, Ijaz B, Khan M, Ahmad W, Ashfaq UA, Hassan S. Effect of combined siRNA of HCV E2 gene and HCV receptors against HCV. Virol J 2011; 8: 295[PMID: 21663667 DOI: 10.1186/1743-422X-8-295]
117. Xue Q, Ding H, Liu M, Zhao P, Gao J, Ren H, Liu Y, Qi ZT. Inhibition of hepatitis C virus replication and expression by small interfering RNA targeting host cellular genes. Arch Virol 2007; 152: 955-962[PMID: 17273891 DOI: 10.1007/s00705-006-0905-x]
118. Korf M, Jarczak D, Beger C, Manns MP, Krüger M. Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors. J Hepatol 2005; 43: 225-234[PMID: 15964661]
119. Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, Sun J, Heathcote J, Rice CM, Edwards AM, McGilvray ID. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterol-ogy 2006; 131: 1584-1591[PMID: 17101330 DOI: 10.1053/ j.gastro.2006.08.043]
120. Nakagawa S, Umehara T, Matsuda C, Kuge S, Sudoh M, Kohara M. Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem Biophys Res Commun 2007; 353: 882-888[PMID: 17196931 DOI: 10.1016/ j.bbrc.2006.12.117]
121. Henry SD, van der Wegen P, Metselaar HJ, Tilanus HW, Scholte BJ, van der Laan LJ. Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol Ther 2006; 14: 485-493[PMID: 16872906 DOI: 10.1016/ j.ymthe.2006.04.012]
122. Khaliq S, Khaliq SA, Zahur M, Ijaz B, Jahan S, Ansar M, Riazuddin S, Hassan S. RNAi as a new therapeutic strategy against HCV. Biotechnol Adv 2010; 28: 27-34[PMID: 19729057 DOI: 10.1016/j.biotechadv.2009.08.004]
123. Ashfaq UA, Yousaf MZ, Aslam M, Ejaz R, Jahan S, Ullah O. siRNAs: potential therapeutic agents against hepatitis C virus. Virol J 2011; 8: 276[PMID: 21645341 DOI: 10.1186/1743-422X-8-276]
124. Wilson JA, Richardson CD. Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J Virol 2005; 79: 7050-7058[PMID: 15890944]
125. Lavender H, Brady K, Burden F, Delpuech-Adams O, Denise H, Palmer A, Perkins H, Savic B, Scott S, Smith-Burchnell C, Troke P, Wright JF, Suhy D, Corbau R. In vitro characterization of the activity of PF-05095808, a novel biological agent for hepatitis C virus therapy. Antimicrob Agents Chemother 2012; 56: 1364-1375[PMID: 22203606 DOI: 10.1128/AAC.05357-11]
126. Suhy DA, Kao SC, Mao T, Whiteley L, Denise H, Souberbi-elle B, Burdick AD, Hayes K, Wright JF, Lavender H, Roel-vink P, Kolykhalov A, Brady K, Moschos SA, Hauck B, Zele-naia O, Zhou S, Scribner C, High KA, Renison SH, Corbau R. Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model. Mol Ther 2012; 20: 1737-1749[DOI: 10.1038/mt.2012.119]
127. Yang X, Haurigot V, Zhou S, Luo G, Couto LB. Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous anti-hepatitis C virus microRNA cluster. Hepatology 2010; 52: 1877-1887[PMID: 20931557 DOI: 10.1002/hep.23908]
128. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537-541[PMID: 16724069 DOI: 10.1038/nature04791]
129. Gupta S, Schoer RA, Egan JE, Hannon GJ, Mittal V. Induc-ible, reversible, and stable RNA interference in mammalian cells. Proc Natl Acad Sci USA 2004; 101: 1927-1932[PMID: 14762164 DOI: 10.1073/pnas.0306111101]
130. Sakamoto N, Tanabe Y, Yokota T, Satoh K, Sekine-Osajima Y, Nakagawa M, Itsui Y, Tasaka M, Sakurai Y, Cheng-Hsin C, Yano M, Ohkoshi S, Aoyagi Y, Maekawa S, Enomoto N, Kohara M, Watanabe M. Inhibition of hepatitis C virus infection and expression in vitro and in vivo by recombinant adenovirus expressing short hairpin RNA. J Gastroenterol Hepatol 2008; 23: 1437-1447[PMID: 17683479]
131. Chandra PK, Kundu AK, Hazari S, Chandra S, Bao L, Ooms T, Morris GF, Wu T, Mandal TK, Dash S. Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes. Mol Ther 2012; 20: 1724-1736[PMID: 22617108 DOI: 10.1038/mt.2012.107]
132. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 259-293[PMID: 20055705 DOI: 10.1146/annurev.parm-tox.010909.105654]
133. Chan JH, Lim S, Wong WS. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 2006; 33: 533-540[PMID: 16700890]
134. Soler M, McHutchison JG, Kwoh TJ, Dorr FA, Pawlotsky JM. Virological effects of ISIS 14803, an antisense oligo-nucleotide inhibitor of hepatitis C virus (HCV) internal ri-bosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment. Antivir Ther 2004; 9: 953-968[PMID: 15651754]
135. McHutchison JG, Patel K, Pockros P, Nyberg L, Pianko S, Yu RZ, Dorr FA, Kwoh TJ. A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J Hepatol 2006; 44: 88-96[PMID: 16274834 DOI: 10.1016/j.jhep.2005.09.009]
136. McCaffrey AP, Meuse L, Karimi M, Contag CH, Kay MA. A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology 2003; 38: 503-508[PMID: 12883495 DOI: 10.1053/jhep.2003.50330]
137. González-Carmona MA, Vogt A, Heinicke T, Quas-dorff M, Hoffmann P, Yildiz Y, Schneider C, Serwe M, Bartenschlager R, Sauerbruch T, Caselmann WH. Inhibition of hepatitis C virus gene expression by adenoviral vectors encoding antisense RNA in vitro and in vivo. J Hepatol 2011; 55: 19-28[PMID: 21145870 DOI: 10.1016/j.jhep.2010.11.010]
138. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309: 1577-1581[PMID: 16141076 DOI: 10.1126/science.1113329]
139. Henke JI, Goergen D, Zheng J, Song Y, Schüttler CG, Fehr C, Jünemann C, Niepmann M. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J 2008; 27: 3300-3310[PMID: 19020517 DOI: 10.1038/emboj.2008.244]
140. Jangra RK, Yi M, Lemon SM. Regulation of hepatitis C virus translation and infectious virus production by the microR-NA miR-122. J Virol 2010; 84: 6615-6625[PMID: 20427538 DOI: 10.1128/JVI.00417-10]
141. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Ørum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201[PMID: 19965718 DOI: 10.1126/science.1178178]
142. Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J. MicroR-NA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. Proc Natl Acad Sci USA 2011; 108: 4991-4996[PMID: 21383155 DOI: 10.1073/pnas.1016606108]
143. Bukh J. Animal models for the study of hepatitis C virus infection and related liver disease. Gastroenterology 2012; 142: 1279-1287.e3 [PMID: 22537434 DOI: 10.1053/ j.gastro.2012.02.016]
144. Dorner M, Horwitz JA, Donovan BM, Labitt RN, Budell WC, Friling T, Vogt A, Catanese MT, Satoh T, Kawai T, Akira S, Law M, Rice CM, Ploss A. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 2013; 501: 237-241[PMID: 23903655 DOI: 10.1038/na-ture12427]